ORLANDO—A small pilot study suggests that magnesium may prevent or delay progression of vascular calcification in hemodialysis patients without a detrimental effect on bone, researchers reported here at the 2008 Annual Dialysis Conference.

The FDA issued an Early Communication regarding its ongoing review of Vytorin (ezetimibe and simvastatin) based on preliminary results from the recently completed ENHANCE (Effect of Combination Ezetimibe and High-Dose Simvastatin vs. Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia) study on this cholesterol-lowering drug.

Elevated plasma levels of urotensin II (UTN) predicts a lower risk of death from all causes and cardiovascular causes in CKD patients, Italian researchers conclude.

ORLANDO—High-dose atorvastatin may preserve renal function in patients with cerebrovascular disease, a study shows.

WASHINGTON, D.C.— Waist-to-hip ratio (WHR) in CKD patients is an independent predictor of cardiac event risk, researchers say.

SAN FRANCISCO—Waist-to-hip ratio (WHR) in CKD patients is an independent predictor of cardiac event risk, data suggest.

PRE-EXISTING coronary artery disease (CAD) decreases survival of patients following renal transplantation, study findings suggest.

BP-LOWERING treatment with perindopril decreases the likelihood of major vascular events and stroke in CKD patients with cerebrovascular disease.

BARCELONA--Pro-inflammatory cytokines are a marker for increased cardiovascular and overall mortality in dialysis patients, new research demonstrates.

ANAHEIM, Calif.—Nephrolithiasis may be associated with a modest but significantly elevated risk of heart disease, according to a new study presented here at American Urological Association annual meeting.